Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer

European Journal of Cancer

Volumn 43, Issue 8, 2007, Pages 1300-1307

  Suhonen, Kirsi A ^a   Anttila, Maarit A ^a   Sillanpää, Sari M ^a   Hämäläinen, Kirsi M ^a   Saarikoski, Seppo V ^a   Juhola, Matti ^b   Kosma, Veli Matti ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Angiogenesis; CD34; Chalkley; Ovarian cancer; Survival

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; PLATINUM COMPLEX;

ADULT; AGED; ANALYTIC METHOD; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 34248212728     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.03.007     Document Type: Article

References (35)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
2. Pezzella F., Harris A.L., and Gatter K.C. Ways of escape: are all tumours angiogenic?. Histopathology 39 (2001) 551-553
3. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
4. Solomon L.A., Munkarah A.R., Schimp V.L., et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 101 (2006) 385-389
5. Ogawa S., Kaku T., Kobayashi H., et al. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 176 (2002) 111-118
6. Birner P., Schindl M., Obermair A., Breitenecker G., and Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
7. Gasparini G., Bonoldi E., Viale G., et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69 (1996) 205-211
8. Hollingsworth H.C., Kohn E.C., Steinberg S.M., Rothenberg M.L., and Merino M.J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147 (1995) 33-41
9. Gadducci A., Viacava P., Cosio S., et al. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res 23 (2003) 549-556
10. Losch A., Schindl M., Kohlberger P., et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 92 (2004) 545-552
11. Nishida N., Yano H., Komai K., Nishida T., Kamura T., and Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101 (2004) 1364-1374
12. Goodheart M.J., Vasef M.A., Sood A.K., Davis C.S., and Buller R.E. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol 86 (2002) 85-90
13. Alvarez A.A., Krigman H.R., Whitaker R.S., Dodge R.K., and Rodriguez G.C. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5 (1999) 587-591
14. Hata K., Nakayama K., Fujiwaki R., Katabuchi H., Okamura H., and Miyazaki K. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 93 (2004) 215-222
15. van Diest P.J., Zevering J.P., Zevering L.C., and Baak J.P. Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients. Pathol Res Pract 191 (1995) 25-30
16. Strauss L.C., Rowley S.D., La Russa V.F., Sharkis S.J., Stuart R.K., and Civin C.I. Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol 14 (1986) 878-886
17. Beschorner W.E., Civin C.I., and Strauss L.C. Localization of hematopoietic progenitor cells in tissue with the anti-My-10 monoclonal antibody. Am J Pathol 119 (1985) 1-4
18. Heimburg S., Oehler M.K., Kristen P., Papadopoulos T., and Caffier H. The endothelial marker CD 34 in the assessment of tumour vascularisation in ovarian cancer. Anticancer Res 17 (1997) 3149-3151
19. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
20. Fox S.B., Leek R.D., Smith K., Hollyer J., Greenall M., and Harris A.L. Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29 (1994) 109-116
21. Vermeulen P.B., Gasparini G., Fox S.B., et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38 (2002) 1564-1579
22. Offersen B.V., Borre M., and Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 39 (2003) 881-890
23. Anttila M.A., Tammi R.H., Tammi M.I., Syrjanen K.J., Saarikoski S.V., and Kosma V.M. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60 (2000) 150-155
24. Hansen S., Grabau D.A., Rose C., Bak M., and Sorensen F.B. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 78 (1998) 1563-1573
25. Fox S.B., Leek R.D., Weekes M.P., Whitehouse R.M., Gatter K.C., and Harris A.L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177 (1995) 275-283
26. Shih I., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
27. Hansen S., Grabau D.A., Sorensen F.B., Bak M., Vach W., and Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6 (2000) 139-146
28. Gasparini G., Fox S.B., Verderio P., et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 2 (1996) 1191-1198
29. Fox S.B., Gatter K.C., Leek R.D., et al. More about: tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 92 (2000) 161-162
30. Makris A., Powles T.J., Kakolyris S., Dowsett M., Ashley S.E., and Harris A.L. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 85 (1999) 1996-2000
31. Nakayama K., Kanzaki A., Takebayashi Y., et al. Different features of angiogenesis between ovarian and breast carcinoma. Cancer Lett 170 (2001) 161-167
32. Vasey P.A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 89 (2003) S23-S28
33. Munn L.L. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8 (2003) 396-403
34. Sood A.K., Fletcher M.S., Zahn C.M., et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 1 (2002) 661-664
35. Maniotis A.J., Folberg R., Hess A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155 (1999) 739-752